"Micromet will make upfront, milestone, and royalty payments to MedImmune related to the development and North American net sales of blinatumomab."

May be why they had to initiate new financing (as previously speculated). Will also be lots of Phase III and product launch expenses to bear. In the Bioworld article on the S-A partnership, Itin said that partnerning MT103 was not a priority, so I assume they are going it alone. (quote below)

Itin said the company is in no hurry to partner, looking ahead to ASH and planning for a pivotal trial in ALL.

"So partnering is really not at the forefront at this time," he added.